AC
TTNP

Armistice Capital’s Titan Pharmaceuticals TTNP Stock Holding History

Armistice Capital’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-43,176
Closed -$826K – 206
2022
Q1 		$826K Buy
+43,176
New +$897K 0.02% 114
2018
Q4 		– Sell
-61
Closed -$46K – 95
2018
Q3 		$46K Buy
+61
New +$166K ﹤0.01% 77

Other funds holding TTNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Armistice Capital's TTNP Position: Q2 2022 in Review

Armistice Capital sold out of Titan Pharmaceuticals (TTNP) in Q2 2022, closing a stake of 43,176 shares — an estimated $826K sold.

Armistice Capital first reported a position in TTNP in Q3 2018 and held it in 2 quarters. The position peaked at $826K in Q1 2022. 19 funds tracked by Wall St. Rank hold TTNP as of Q2 2022.

  • Armistice Capital reported no remaining Titan Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Armistice Capital sold 43,176 Titan Pharmaceuticals shares in Q2 2022, an estimated $826K.
  • Armistice Capital first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Armistice Capital's Titan Pharmaceuticals position peaked at $826K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2022.

Based on Armistice Capital's 13F filing for Q2 2022, filed 15 Aug 2022.